Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | NSCLC | Research

A cuproptosis score model and prognostic score model can evaluate clinical characteristics and immune microenvironment in NSCLC

Authors: Yijie Tang, Tianyi Wang, Qixuan Li, Jiahai Shi

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Background

Cuproptosis-related genes (CRGs) are associated with lung adenocarcinoma. However, the links between CRGs and non-small-cell lung cancer (NSCLC) are not clear. In this study, we aimed to develop two cuproptosis models and investigate their correlation with NSCLC in terms of clinical features and tumor microenvironment.

Methods

CRG expression profiles and clinical data from NSCLC and normal tissues was obtained from GEO (GSE42127) and TCGA datasets. Molecular clusters were classified into three patterns based on CRGs and cuproptosis cluster-related specific differentially expressed genes (CRDEGs). Then, two clinical models were established. First, a prognostic score model based on CRDEGs was established using univariate/multivariate Cox analysis. Then, through principal component analysis, a cuproptosis score model was established based on prognosis-related genes acquired via univariate analysis of CRDEGs. NSCLC patients were divided into high/low risk groups.

Results

Eighteen CRGs were acquired, all upregulated in tumor tissues, 15 of which significantly (P < 0.05). Among the three CRG clusters, cluster B had the best prognosis. In the CRDEG clusters, cluster C had the best survival. In the prognostic score model, the high-risk group had worse prognosis, higher tumor mutation load, and lower immune infiltration while in the cuproptosis score model, a high score represented better survival, lower tumor mutation load, and high-level immune infiltration.

Conclusions

The cuproptosis score model and prognostic score model may be associated with NSCLC prognosis and immune microenvironment. These novel findings on the progression and immune landscape of NSCLC may facilitate the provision of more personalized immunotherapy interventions for NSCLC patients.
Appendix
Available only for authorised users
Literature
1.
2.
Park K, Vansteenkiste J, Lee K, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon P, Tan D, Yang J, et al. Pan-asian adapted ESMO Clinical Practice guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Annals Oncology: Official J Eur Soc Med Oncol. 2020;31(2):191–201.CrossRef
3.
Cronin K, Lake A, Scott S, Sherman R, Noone A, Howlader N, Henley S, Anderson R, Firth A, Ma J, et al. Annual Report to the Nation on the Status of Cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785–800.PubMedCrossRef
4.
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40.PubMedPubMedCentralCrossRef
5.
Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, Chow L, Vokes E, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-small-cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.PubMedPubMedCentralCrossRef
6.
Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies. Lung Cancer. 2022;170:41–51.PubMedCrossRef
7.
Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2021. Cancer J Clin. 2021;71(1):7–33.CrossRef
8.
Leiter A, Veluswamy R, Wisnivesky J. The global burden of lung cancer: current status and future trends. Nat Reviews Clin Oncol. 2023;20(9):624–39.CrossRef
9.
Keek S, Kayan E, Chatterjee A, Belderbos J, Bootsma G, van den Borne B, Dingemans A, Gietema H, Groen H, Herder J, et al. Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC. Therapeutic Adv Med Oncol. 2022;14:17588359221116605.
10.
Kandathil A, Subramaniam R. FDG PET/CT for primary staging of Lung Cancer and Mesothelioma. Semin Nucl Med. 2022;52(6):650–61.PubMedCrossRef
11.
12.
Ashkenazi A, Salvesen G. Regulated cell death: signaling and mechanisms. Annu Rev Cell Dev Biol. 2014;30:337–56.PubMedCrossRef
13.
Strasser A, Vaux DL. Cell death in the origin and treatment of Cancer. Mol Cell. 2020;78(6):1045–54.PubMedCrossRef
14.
15.
Santagostino S, Assenmacher C, Tarrant J, Adedeji A, Radaelli E. Mechanisms of regulated cell death: current perspectives. Vet Pathol. 2021;58(4):596–623.PubMedCrossRef
16.
Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler R, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Sci (New York NY). 2022;375(6586):1254–61.ADSCrossRef
17.
Ge E, Bush A, Casini A, Cobine P, Cross J, DeNicola G, Dou Q, Franz K, Gohil V, Gupta S, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22(2):102–13.PubMedCrossRef
18.
Liu Y, Bager C, Willumsen N, Ramchandani D, Kornhauser N, Ling L, Cobham M, Andreopoulou E, Cigler T, Moore A, et al. Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. NPJ Breast cancer. 2021;7(1):108.PubMedPubMedCentralCrossRef
19.
Voli F, Valli E, Lerra L, Kimpton K, Saletta F, Giorgi F, Mercatelli D, Rouaen J, Shen S, Murray J, et al. Intratumoral Copper modulates PD-L1 expression and influences Tumor Immune Evasion. Cancer Res. 2020;80(19):4129–44.PubMedCrossRef
20.
Sha S, Si L, Wu X, Chen Y, Xiong H, Xu Y, Liu W, Mei H, Wang T, Li M. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer. Front Immunol. 2022;13:922780.PubMedPubMedCentralCrossRef
21.
Zhou Y, Shu Q, Fu Z, Wang C, Gu J, Li J, Chen Y, Xie M. A novel risk model based on cuproptosis-related lncRNAs predicted prognosis and indicated immune microenvironment landscape of patients with cutaneous melanoma. Front Genet. 2022;13:959456.PubMedPubMedCentralCrossRef
22.
Mo X, Hu D, Yang P, Li Y, Bashir S, Nai A, Ma F, Jia G, Xu M. A novel cuproptosis-related prognostic lncRNA signature and lncRNA MIR31HG/miR-193a-3p/TNFRSF21 regulatory axis in lung adenocarcinoma. Front Oncol. 2022;12:927706.PubMedPubMedCentralCrossRef
23.
Song Q, Zhou R, Shu F, Fu W. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer. Front Immunol. 2022;13:958368.PubMedPubMedCentralCrossRef
24.
Ma S, Zhu J, Wang M, Zhu J, Wang W, Xiong Y, Jiang R, Seetharamu N, Abrão F, Puthamohan V, et al. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. Translational lung cancer Res. 2022;11(10):2079–93.CrossRef
25.
Li Q, Wang T, Zhou Y, Shi J. Cuproptosis in lung cancer: mechanisms and therapeutic potential. Molecular and cellular biochemistry 2023.
26.
Ma C, Li F, Gu Z, Yang Y, Qi Y. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma. Front Pharmacol. 2023;14:1146840.PubMedPubMedCentralCrossRef
27.
Xiaona X, Liu Q, Zhou X, Liang R, Yang S, Xu M, Zhao H, Li C, Chen Y, Xueding C. Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in lung adenocarcinoma. Comput Biol Med. 2023;158:106831.PubMedCrossRef
28.
Ling X, Zhang L, Fang C, Liang H, Zhu J, Ma J. Development of a cuproptosis-related signature for prognosis prediction in lung adenocarcinoma based on WGCNA. Translational lung cancer Res. 2023;12(4):754–69.CrossRef
29.
Duan W, He R. Cuproptosis: copper-induced regulated cell death. Sci China Life Sci. 2022;65(8):1680–2.PubMedCrossRef
30.
Eberst G, Vernerey D, Laheurte C, Meurisse A, Kaulek V, Cuche L, Jacoulet P, Almotlak H, Lahourcade J, Gainet-Brun M, et al. Prognostic value of CD4 + T lymphopenia in non-small cell lung Cancer. BMC Cancer. 2022;22(1):529.PubMedPubMedCentralCrossRef
31.
Zhang G, Liu A, Yang Y, Xia Y, Li W, Liu Y, Zhang J, Cui Q, Wang D, Liu X, et al. Clinical predictive value of naïve and memory T cells in advanced NSCLC. Front Immunol. 2022;13:996348.PubMedPubMedCentralCrossRef
32.
Lin A, Wei T, Meng H, Luo P, Zhang J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 2019;18(1):139.PubMedPubMedCentralCrossRef
33.
Wang C, Li Y, Jia L, Kim J, Li J, Deng P, Zhang W, Krebsbach P, Wang C. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021;28(9):1597–1613e1597.PubMedPubMedCentralCrossRef
34.
Gao W, Huang Z, Duan J, Nice E, Lin J, Huang C. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A. Mol Oncol. 2021;15(12):3527–44.PubMedPubMedCentralCrossRef
35.
Guo H, Ouyang Y, Yin H, Cui H, Deng H, Liu H, Jian Z, Fang J, Zuo Z, Wang X, et al. Induction of autophagy via the ROS-dependent AMPK-mTOR pathway protects copper-induced spermatogenesis disorder. Redox Biol. 2022;49:102227.PubMedCrossRef
36.
Cai H, Peng F. Knockdown of copper chaperone antioxidant-1 by RNA interference inhibits copper-stimulated proliferation of non-small cell lung carcinoma cells. Oncol Rep. 2013;30(1):269–75.PubMedPubMedCentralCrossRef
37.
Li Z, Qiu M, Zeng Z, Luo H, Wu W, Wang F, Wang Z, Zhang D, Li Y, Xu R. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). J Translational Med. 2012;10:21.CrossRef
38.
Wu X, Xue X, Wang L, Wang W, Han J, Sun X, Zhang H, Liu Y, Che X, Yang J, et al. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer. Eur J Pharmacol. 2018;827:1–12.PubMedCrossRef
39.
40.
Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Therapy. 2022;7(1):378.CrossRef
41.
42.
Cobine P, Brady D. Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death. Mol Cell. 2022;82(10):1786–7.PubMedCrossRef
43.
Xu F, Zhang H, Chen J, Lin L, Chen Y. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma. Int Immunopharmacol. 2020;81:105932.PubMedCrossRef
44.
Salama M, Liu M, Clarke C, Espaillat M, Haley J, Jin T, Wang D, Obeid L, Hannun Y. PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation. Oncogene. 2019;38(48):7311–28.PubMedPubMedCentralCrossRef
45.
Osmani L, Askin F, Gabrielson E, Li Q. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Sem Cancer Biol. 2018;52:103–9.CrossRef
46.
Lai Y, Lin C, Lin X, Wu L, Zhao Y, Lin F. Identification and immunological characterization of cuproptosis-related molecular clusters in Alzheimer’s disease. Front Aging Neurosci. 2022;14:932676.PubMedPubMedCentralCrossRef
47.
Talebian Yazdi M, van Riet S, van Schadewijk A, Fiocco M, van Hall T, Taube C, Hiemstra P, van der Burg S. The positive prognostic effect of stromal CD8 + tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget. 2016;7(3):3477–88.PubMedCrossRef
48.
Xia L, Wang H, Sun M, Yang Y, Yao C, He S, Duan H, Xia W, Sun R, Yao Y, et al. Peripheral CD4 T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. Sci China Life Sci. 2021;64(10):1590–601.ADSPubMedCrossRef
Metadata
Title
A cuproptosis score model and prognostic score model can evaluate clinical characteristics and immune microenvironment in NSCLC
Authors
Yijie Tang
Tianyi Wang
Qixuan Li
Jiahai Shi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03267-8

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningioma

Research

p53 activation enhances the sensitivity of non-small cell lung cancer to the combination of SH003 and docetaxel by inhibiting de novo pyrimidine synthesis

Research

Development and validation of a disulfidptosis and disulfide metabolism-related risk index for predicting prognosis in lung adenocarcinoma

Review

The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target

Research

Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma

Research

Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits